Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
$4.60
$4.62
$4.53
$4.76
$1.56B-0.52N/AN/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$4.28
$4.18
$3.15
$5.68
$453.12M1.1456 shsN/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
$4.95
+0.7%
$4.00
$2.33
$10.53
$1.96B1.7179,657 shs31,100 shs
Pharma Mar stock logo
PHMMF
Pharma Mar
$92.57
$92.28
$34.26
$105.60
N/A0.222,034 shs2,550 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
0.00%0.00%0.00%+16.19%+5.41%
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
0.00%0.00%+8.91%+9.65%+4.30%
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
+0.61%+2.50%+23.31%+40.17%-41.98%
Pharma Mar stock logo
PHMMF
Pharma Mar
0.00%-11.41%-3.77%-9.32%+197.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/AN/AN/AN/AN/AN/AN/AN/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/AN/AN/AN/AN/AN/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
0.5995 of 5 stars
0.01.00.00.02.20.01.9
Pharma Mar stock logo
PHMMF
Pharma Mar
0.0496 of 5 stars
0.03.00.00.00.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
0.00
N/AN/AN/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
0.00
N/AN/AN/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
2.00
HoldN/AN/A
Pharma Mar stock logo
PHMMF
Pharma Mar
4.00
Strong BuyN/AN/A

Current Analyst Ratings Breakdown

Latest OXBDF, PHMMF, OERLF, and PALAF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/14/2025
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/26/2025
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
$2.69B0.58$0.76 per share6.03$3.79 per share1.21
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
$111.34M4.07N/AN/A$1.01 per share4.23
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
$4.70M420.34N/AN/A$1.33 per share3.72
Pharma Mar stock logo
PHMMF
Pharma Mar
$189.23MN/A$0.41 per share223.50$11.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
$74.97MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
-$195.90MN/A0.00N/AN/AN/AN/AN/AN/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
$53.63MN/A0.0017.08N/AN/AN/AN/A9/4/2025 (Estimated)
Pharma Mar stock logo
PHMMF
Pharma Mar
$28.27MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/AN/AN/AN/AN/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/AN/AN/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
N/AN/AN/AN/AN/A
Pharma Mar stock logo
PHMMF
Pharma Mar
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
0.15
1.09
0.76
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/AN/AN/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
0.21
3.74
2.23
Pharma Mar stock logo
PHMMF
Pharma Mar
0.20
2.97
2.33

Institutional Ownership

CompanyInstitutional Ownership
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
0.01%
Pharma Mar stock logo
PHMMF
Pharma Mar
N/A

Insider Ownership

CompanyInsider Ownership
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
N/A
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
N/A
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
N/A
Pharma Mar stock logo
PHMMF
Pharma Mar
1.88%
CompanyEmployeesShares OutstandingFree FloatOptionable
Oc Oerlikon Cp stock logo
OERLF
Oc Oerlikon Cp
12,064339.76 millionN/ANot Optionable
Oxford BioMedica stock logo
OXBDF
Oxford BioMedica
891105.96 millionN/ANot Optionable
Paladin Energy Ltd. stock logo
PALAF
Paladin Energy
307398.91 millionN/ANot Optionable
Pharma Mar stock logo
PHMMF
Pharma Mar
509N/AN/ANot Optionable

Recent News About These Companies

Pharma Mar’s Strategic Shareholder Meeting
ASCO 25: Jazz, PharmaMar reveal SCLC survival data
Exploring High Growth Tech Stocks In Europe May 2025
Exploring High Growth Tech Stocks in Europe April 2025
Pharma Mar Releases 2024 Director Remuneration Report
High Growth Tech Leads These 3 Top Stocks with Potential
3 Stocks Estimated To Be Up To 48% Below Intrinsic Value
Insider-Led Growth Stocks To Watch In December 2024
Pharma Mar S.A. Reduces Share Capital by Canceling Shares
Pharma Mar Achieves Legal Win in Aplidin Case
PharmaMar gets $10 million milestone from Janssen for Yondelis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Oc Oerlikon Cp stock logo

Oc Oerlikon Cp OTCMKTS:OERLF

$4.60 0.00 (0.00%)
As of 06/24/2025

OC Oerlikon Corporation AG provides surface engineering, polymer processing, and additive manufacturing services in Switzerland, Americas, the Asia-Pacific, and Europe. The company operates through two segments, Surface Solutions and Polymer Processing. It offers engine fan compressors, engine hot section, landing gears, actuation systems, aircraft interior, and hydraulic systems for aerospace; engine and brake systems, transmission, drive train, steering and suspension, exhaust systems, piping and tubing systems, exterior, lighting, green hydrogen, interior, heat exchanger and EGR coolers, peripherals and design parts, and thermal insulation systems for automotive; and oil and gas, and boilers, as well as hydro, gas, steam, and wind turbines for energy industry. In addition, the company offers cutting, metal forming, plastic processing, and die casting for tooling industry; additives, coatings, conductive filler materials, control units, thermal spray systems and components, face to face systems, valve fate systems, hot valves, hot runner systems, single nozzles, stack molds, surface solutions, and valve gates group single nozzles; AM metal powder for additive manufacturing; polymer processing for textile and apparel, functional wear, transportation, packaging, flooring and textile, medical and fiber, and infrastructure; and spine implants, medical, artificial joints, dental and veterinary implants, and surgical and minimally invasive surgical instruments for medical industry. It serves surface solutions under Oerlikon Balzers, Oerlikon Metco, and Oerlikon AM ; and polymer processing solutions under Oerlikon Barmag, Oerlikon Neumag, Oerlikon Nonwoven, and Oerlikon HRSFlow name. OC Oerlikon Corporation AG was founded in 1907 and is headquartered in Pfäffikon, Switzerland.

Oxford BioMedica stock logo

Oxford BioMedica OTCMKTS:OXBDF

$4.28 0.00 (0.00%)
As of 06/23/2025

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Paladin Energy stock logo

Paladin Energy OTCMKTS:PALAF

$4.95 +0.03 (+0.66%)
As of 03:59 PM Eastern

Paladin Energy Ltd develops, explores for, owns, and operates uranium mines in Australia, Canada, and Africa. The company operates through Exploration, Namibia, and Australia segments. Its flagship project is the Langer Heinrich mine located in the Namib Desert in Namibia. The company was formerly known as Paladin Resources Ltd and changed its name to Paladin Energy Limited in November 2007. Paladin Energy Ltd was incorporated in 1993 and is headquartered in Perth, Australia.

Pharma Mar stock logo

Pharma Mar OTCMKTS:PHMMF

$92.57 0.00 (0.00%)
As of 06/24/2025

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.